Skip to main content

Advertisement

SpringerLink
Log in

Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer’s disease?

胰高血糖素样多肽1 — 治疗糖尿病的多肽, 是治疗阿尔茨海默病的新希望?

  • Minireview
  • Published:
Neuroscience Bulletin Aims and scope Submit manuscript

Abstract

Glucagon-like peptide-1 (GLP-1) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM). Both Alzheimer’s disease (AD) and T2DM share some common pathophysiologic hallmarks, such as amyloid β(Aβ), phosphoralation of tau protein, and glycogen synthase kinase-3. GLP-1 possesses neurotropic properties and can reduce amyloid protein levels in the brain. Based on extensive studies during the past decades, the understanding on AD leads us to believe that the primary targets in AD are the Aβ and tau protein. Combine these findings, GLP-1 is probably a promising agent in the therapy of AD. This review was focused on the biochemistry and physiology of GLP-1, communities between T2DM and AD, new progresses of GLP-1 in treating T2MD and improving some pathologic hallmarks of AD.

摘要

胰高血糖素样多肽1(Glucagon-like peptide, GLP)已被证明是有前景的II型糖尿病(Type 2 diabetes mellitus, T2DM)治疗剂。 阿尔茨海默病(Alzheimer’s disease, AD)和T2DM具有在淀粉样蛋 β(Amyloid β, Aβ), tau 蛋白磷酸化和葡萄糖合成酶3等方面的共同的病理生理特征。 GLP-1 具有神经营养特性, 并能降低脑淀粉样蛋白水平。 过去几十年对AD的广泛研究使我们认识到对其治疗应针对Aβ 和 tau 蛋白。 总结这些之后发现, GLP-1 可能有希望用于治疗AD。 本文综述了GLP-1的生物化学和生理学特征, T2DM和AD的共同的病理生理特征, 以及GLP-1 在治疗T2MD和改善AD某些病理变化方面的新进展。

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994, 107:1848–1855.

    PubMed  CAS  Google Scholar 

  2. Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 2004, 47: 4128–4134.

    Article  PubMed  CAS  Google Scholar 

  3. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992, 326: 1316–1322.

    Article  PubMed  CAS  Google Scholar 

  4. Creutzfeldt W. The incretin concept today. Diabetologia 1979, 16: 75–85.

    Article  PubMed  CAS  Google Scholar 

  5. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141: 4600–4605.

    Article  PubMed  CAS  Google Scholar 

  6. Hui H, Zhao X, Perfetti R. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev 2005, 21: 313–331.

    Article  PubMed  CAS  Google Scholar 

  7. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al. Glucagon-like peptide-1 decreases endogenous amyloid β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J Neurosci Res 2003, 72: 603–612.

    Article  PubMed  CAS  Google Scholar 

  8. Satoh F, Beak SA, Small CJ, Falzon M, Ghatei MA, Bloom SR, et al. Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocreology 2000, 141: 1301–1309.

    Article  CAS  Google Scholar 

  9. Perry T, Greig NH. The glucagon-like peptides: a new genre in therapeautic targets for intervention in Alzheimer’s disease. J Alzheimer Dis 2002, 4: 487–496.

    CAS  Google Scholar 

  10. Perry T, Greig NH. A new Alzheimer’s disease interventive strategy: GLP-1. Curr Drug Targets 2004, 5: 565–571.

    Article  PubMed  CAS  Google Scholar 

  11. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer’s disease. Curr Alzheimer Res 2005, 2: 377–385.

    Article  PubMed  CAS  Google Scholar 

  12. Bell GI. The glucagon superfamily: precursor structure and gene organization. Peptides 1986, 7(Suppl 1): 27–36.

    Article  PubMed  CAS  Google Scholar 

  13. Suda K, Takahashi H, Fukase N, Manaka H, Tominaga M, Sasaki H. Distribution and molecular forms of glucagon-like peptide in the dog. Life Sci 1989, 45: 1793–1798.

    Article  PubMed  CAS  Google Scholar 

  14. Rouille Y, Martin S, Steiner DF. Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide. J Biol Chem 1995, 270: 26488–26496.

    Article  PubMed  CAS  Google Scholar 

  15. Wettergren A, Pridal L, Wojdemann M, Holst JJ. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul Pept 1998, 77: 83–87.

    Article  PubMed  CAS  Google Scholar 

  16. Nauck MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol 1998, 35: 117–129.

    Article  PubMed  CAS  Google Scholar 

  17. Demuth HU, McIntosch CH, Pederson RA. Type 2 diabetestherapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005, 1751: 33–45.

    PubMed  CAS  Google Scholar 

  18. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7–36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996, 318: 429–435.

    Article  PubMed  CAS  Google Scholar 

  19. Schmidtler J, Schepp W, Janczewska I, Weigert N, Furlinger C, Schusdziarra V, et al. GLP-1-(7–36) amide,-(1-37), and-(1-36) amide: potent cAMP-dependent stimuli of rat parietal cell function. Am J Physiol 1991, 260: G940–G950.

    PubMed  CAS  Google Scholar 

  20. Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, et al. Normalization of fasting glycaemia by intravenous GLP-1 [(7–36 amide) or (7–37)] in type 2 diabetes patients. Diabet Med 1988, 15: 937–945.

    Article  Google Scholar 

  21. Deacon CF, Plamboeck A, Moller S, Holst JJ. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 2002, 282: E873–E879.

    PubMed  CAS  Google Scholar 

  22. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7–36) amide in patients with NIDDM. Diabetes 1996, 45: 1524–1530.

    Article  PubMed  CAS  Google Scholar 

  23. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glu cagon-like peptide 1 (7–36 amide) in type 2 (non-insulindependent) diabetic patients. Diabetologia 1993, 36: 741–744.

    Article  PubMed  CAS  Google Scholar 

  24. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996, 81: 327–332.

    Article  PubMed  CAS  Google Scholar 

  25. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22: 1137–1143.

    Article  PubMed  CAS  Google Scholar 

  26. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359: 824–830.

    Article  PubMed  CAS  Google Scholar 

  27. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002, 122: 531–544.

    Article  PubMed  CAS  Google Scholar 

  28. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003, 3: 365–372.

    Article  PubMed  Google Scholar 

  29. Huang THJ, Brubaker PL. Synthesis and secretion of glucagon-like peptide-1 by fetal rat intestinal cells in culture. Endocrine 1995, 3: 499–503.

    Article  CAS  Google Scholar 

  30. Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001, 50: 1720–1728.

    Article  PubMed  CAS  Google Scholar 

  31. Dardevet D, Moore MC, DiCostanzo CA, Farmer B, Neal DW, Snead W, et al. Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol 2005, 289: G806–G814.

    Article  PubMed  CAS  Google Scholar 

  32. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005, 48: 612–615.

    Article  PubMed  CAS  Google Scholar 

  33. Ionut V, Hucking K, Liberty IF, Bergman RN. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 2005, 48: 967–975.

    Article  PubMed  CAS  Google Scholar 

  34. Combettes MM. GLP-1 and type 2 diabetes: physiology and new clinical advances. Current Opin Pharmacol 2006, 6: 598–605.

    Article  CAS  Google Scholar 

  35. Raufman JP. Bioactive peptides from lizard venoms. Regul Pept 1996, 61: 1–18.

    Article  PubMed  CAS  Google Scholar 

  36. Stoffel M, Espinosa R 3rd, Le Beau MM, Bell GI. Human glucagon-like peptide-1 receptor gene. Localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6. Diabetes 1993, 42: 1215–1218.

    Article  PubMed  CAS  Google Scholar 

  37. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994, 134: 2156–2164.

    Article  PubMed  CAS  Google Scholar 

  38. Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, Boyd AE. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 1993, 133: 57–62.

    Article  PubMed  CAS  Google Scholar 

  39. Wilmen A, Van Eyll B, Goke B, Goke R. Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1. Peptides 1997, 18: 301–305.

    Article  PubMed  CAS  Google Scholar 

  40. Salapatek AM, MacDonald PE, Gaisano HY, Wheeler MB. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells. Mol Endocrinol 1999, 13: 1305–1317.

    Article  PubMed  CAS  Google Scholar 

  41. Margolis RU, Altszuler N. Insulin in the cerebrospinal fluid. Nature 1967, 215: 1375–1376.

    Article  PubMed  CAS  Google Scholar 

  42. Havrankova J, Schmechel D, Roth J, Brownstein M. Identification of insulin in rat brain. Proc Natl Acad Sci USA 1978, 75: 5737–5741.

    Article  PubMed  CAS  Google Scholar 

  43. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978, 272: 827–829.

    Article  PubMed  CAS  Google Scholar 

  44. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006, 27: 570–575.

    Article  PubMed  CAS  Google Scholar 

  45. Churcher I. Tau therapeutic strategies for the treatment of Alzheimer’s disease. Curr Top Med Chem 2006, 6: 579–595.

    Article  PubMed  CAS  Google Scholar 

  46. Roche E, Reig JA, Campos A, Paredes B, Isaac JR, Lim S, et al. Insulin-secreting cells derived from stem cells: clinical perspectives, hypes and hopes. Transpl Immunol 2005, 15: 113–129.

    Article  PubMed  CAS  Google Scholar 

  47. Mosselman S, Hoppener JW, Zandberg J, van Mansfeld AD, Geurts van Kessel AH, Lips CJ, et al. Islet amyloid polypeptide: identification and chromosomal localization of the human gene. FEBS Lett 1988, 239: 227–232.

    Article  PubMed  CAS  Google Scholar 

  48. Hoppener JW, Ahren B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000, 343: 411–419.

    Article  PubMed  CAS  Google Scholar 

  49. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53: 474–481.

    Article  PubMed  CAS  Google Scholar 

  50. Razay G, Wilcock GK. Hyperinsulinaemia and Alzheimer’s disease. Age Ageing 1994, 23: 396–399.

    Article  PubMed  CAS  Google Scholar 

  51. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PC, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997, 145: 301–308.

    PubMed  CAS  Google Scholar 

  52. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53: 1937–1942.

    PubMed  CAS  Google Scholar 

  53. Stolk RP, Breteler MM, Ott A, Pols HA, Lamberts SW, Grobbee DE, et al. Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care 1997, 20: 792–795.

    Article  CAS  Google Scholar 

  54. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, et al. Insulin increases CSF Aâ42 levels in normal older adults. Neurology 2003, 60: 1899–1903.

    PubMed  CAS  Google Scholar 

  55. Wolozin B. Cholesterol and Alzheimer’s disease. Biochem Soc Trans 2002, 30: 525–529.

    Article  PubMed  CAS  Google Scholar 

  56. Reaven GM, Bernstein R, Davis B, Olefsky JM. Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med 1976, 60: 80–88.

    Article  PubMed  CAS  Google Scholar 

  57. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 1996, 93: 7283–7288.

    Article  PubMed  CAS  Google Scholar 

  58. Verchere CB, D’Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, et al. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 1996, 93: 3492–3496.

    Article  PubMed  CAS  Google Scholar 

  59. Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Tornell J, Westermark P, et al. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 1998, 250: 271–277.

    Article  PubMed  CAS  Google Scholar 

  60. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid â-protein, and the â-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003, 100: 4162–4167.

    Article  PubMed  CAS  Google Scholar 

  61. Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, Krone W, et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 2005, 54: 3343–3348.

    Article  PubMed  CAS  Google Scholar 

  62. Sivaprakasam P, Xie A, Doerksen RJ. Probing the physicochemical and structural requirements for glycogen synthase kinase-3α inh ib it ion: 2D-QSAR for 3-ani li no-4-phenylmaleimides. Bioorg Med Chem 2006, 14: 8210–8218.

    Article  PubMed  CAS  Google Scholar 

  63. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3á regulates production of Alzheimer’s disease amyloid-â peptides. Nature 2003, 423: 435–439.

    Article  PubMed  CAS  Google Scholar 

  64. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004, 89: 1313–1317.

    Article  PubMed  CAS  Google Scholar 

  65. Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord 2003, 3: 3–12.

    Article  PubMed  Google Scholar 

  66. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 1998, 435: 583–594.

    Article  PubMed  CAS  Google Scholar 

  67. Mattson MP, Lovell MA, Furukawa K, Markesbery WR. Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 1995, 65: 1740–1751.

    Article  PubMed  CAS  Google Scholar 

  68. Kumar M, Hunag Y, Glinka Y, Prud’homme GJ, Wang Q. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Therapy 2006, Aug 31. Epub ahead of print.

  69. Sinclair EM, Drucker DJ. Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabet 2005, 12: 146–151.

    Article  CAS  Google Scholar 

  70. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture 2005. Diabetologia 2006, 49: 253–260.

    Article  PubMed  CAS  Google Scholar 

  71. Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005, 31: 233–242.

    Article  PubMed  CAS  Google Scholar 

  72. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997, 273: G920–G927.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gerontology Institute, Shanxi Medical University, Taiyuan, 030001, China

    Lin Li

Authors
  1. Lin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lin Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, L. Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer’s disease?. Neurosci. Bull. 23, 58–65 (2007). https://doi.org/10.1007/s12264-007-0009-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-007-0009-y

Keywords

CLC number

关键词

Search

Navigation